Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNT for Locally Advanced Rectal Cancer
NCT07581626Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, KL-140 and bevacizumab in rectal cancer, sponsored by Chinese PLA General Hospital. Primary endpoint: Complete Response. Planned start May 2026; status: not yet recruiting.
02
Drugs
sintilimabKL-140bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07581626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07581626.